Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Furuse · SciRah

Researcher profile · Semantic Scholar

J. Furuse

Share profile

J. Furuse — researcher profile on SciRah

h-index: 75
Works: 587
Citations: 26K

Most-cited papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
G. Abou-Alfa, G. Lau, M. Kudo, S. Chan +27 more
2022NEJM Evidence1,247 citations Open access
Semantic Scholar
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
T. Yau, Joong-Won Park, R. Finn, A. Cheng +23 more
2021The Lancet Oncology930 citations
Semantic Scholar
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
R. K. Kelley, M. Ueno, C. Yoo, R. Finn +17 more
2023The Lancet882 citations Open access
Semantic Scholar
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, J. Valle +26 more
2023New England Journal of Medicine505 citations Open access
Semantic Scholar
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
K. Hasegawa, N. Takemura, T. Yamashita, T. Watadani +23 more
2023Hepatology Research315 citations Open access
Semantic Scholar
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
G. Abou-Alfa, S. Chan, M. Kudo, G. Lau +16 more
2022Journal of Clinical Oncology311 citations
Semantic Scholar
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
K. Nakachi, M. Ikeda, M. Konishi, S. Nomura +16 more
2023The Lancet195 citations
Semantic Scholar
Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis
T. Okusaka, Masafumi Nakamura, Masahiro Yoshida, Masayuki Kitano +130 more
2023International Journal of Clinical Oncology144 citations Open access
Semantic Scholar
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
M. Kudo, K. Ueshima, M. Ikeda, T. Torimura +23 more
2022Liver Cancer139 citations Open access
Semantic Scholar
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System
C. Morizane, N. Machida, Y. Honma, T. Okusaka +17 more
2022JAMA Oncology107 citations Open access
Semantic Scholar
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
M. Kudo, K. Ueshima, I. Saeki, T. Ishikawa +22 more
2023Liver Cancer103 citations Open access
Semantic Scholar
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
M. Ozaka, K. Nakachi, Satoshi Kobayashi, A. Ohba +25 more
2022European Journal of Cancer89 citations Open access
Semantic Scholar
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
A. Ohba, C. Morizane, M. Ueno, Satoshi Kobayashi +16 more
2022Future Oncology60 citations Open access
Semantic Scholar
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
M. Kudo, K. Motomura, Y. Wada, Y. Inaba +9 more
2021Liver Cancer57 citations Open access
Semantic Scholar
Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
L. Goyal, F. Meric-Bernstam, A. Hollebecque, C. Morizane +16 more
2022Journal of Clinical Oncology48 citations
Semantic Scholar
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
C. Yoo, M. Javle, Helena Verdaguer Mata, F. De Braud +16 more
2023Hepatology43 citations Open access
Semantic Scholar
A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
T. Naito, J. Uchino, Toru Kojima, Yutaka Matano +11 more
2022Cancer38 citations Open access
Semantic Scholar
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
M. Ikeda, T. Yamashita, S. Ogasawara, M. Kudo +12 more
2023Liver Cancer37 citations Open access
Semantic Scholar
TACTICS: Final overall survival (OS) data from a randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients (pts) with hepatocellular carcinoma (HCC).
M. Kudo, K. Ueshima, M. Ikeda, T. Torimura +16 more
202131 citations
Semantic Scholar
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
M. Kudo, K. Tsuchiya, N. Kato, A. Hagihara +11 more
2021Journal of gastroenterology27 citations Open access
Semantic Scholar
Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment
H. Imaoka, M. Ikeda, K. Umemoto, Y. Sunakawa +20 more
2023Japanese Journal of Clinical Oncology25 citations Open access
Semantic Scholar
Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
L. Goyal, F. Meric-Bernstam, A. Hollebecque, C. Morizane +16 more
2021Clinical Trials24 citations
Semantic Scholar
SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
B. Sangro, S. Chan, R. Kelley, G. Lau +18 more
2023Annals of Oncology22 citations Open access
Semantic Scholar
Treatments for elderly cancer patients and reforms to social security systems in Japan
F. Nagashima, J. Furuse
2022International Journal of Clinical Oncology21 citations Open access
Semantic Scholar
714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
S. Chan, M. Kudo, B. Sangro, R. K. Kelley +16 more
2022Annals of Oncology20 citations Open access
Semantic Scholar
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
G. Abou-Alfa, G. Lau, Masatoshi Kudo, S. L. Chan +26 more
2023Future Oncology18 citations Open access
Semantic Scholar
Response Evaluation Criteria in Cancer of the Liver version 6 (RECICL 2021 Revised Version).
M. Kudo, M. Ikeda, K. Ueshima, M. Sakamoto +9 more
2022Hepatology Research17 citations Open access
Semantic Scholar
Helmholtz: A Verifier for Tezos Smart Contracts Based on Refinement Types
Y. Nishida, Hiromasa Saito, Ran Chen, Akira Kawata +3 more
2021New generation computing16 citations Open access
Semantic Scholar
Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study.
J. Furuse, M. Ikeda, M. Ueno, M. Furukawa +12 more
2023Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Management of elderly patients with unresectable pancreatic cancer.
Satoshi Kobayashi, M. Ueno, H. Ishii, J. Furuse
2022Japanese Journal of Clinical Oncology13 citations
Semantic Scholar
Randomized multicenter phase III trial of neoadjuvant gemcitabine + cisplatin + S-1 (GCS) versus surgery first for resectable biliary tract cancer (JCOG1920: NABICAT).
S. Nara, T. Ioka, G. Ogawa, T. Kataoka +16 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.
W. Park, E. O'Reilly, J. Furuse, Chung-Pin Li +8 more
2023Journal of Clinical Oncology12 citations
Semantic Scholar
O-5 Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
Arndt Vogel, S. Chan, J. Furuse, W. Tak +10 more
2022Annals of Oncology11 citations Open access
Semantic Scholar
Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
Y. Yoshida, Satoshi Kobayashi, M. Ueno, C. Morizane +27 more
2022Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]11 citations
Semantic Scholar
Response Evaluation Criteria in Cancer of the liver version 6 (Response Evaluation Criteria in Cancer of the Liver 2021 revised version)
M. Kudo, M. Ikeda, K. Ueshima, M. Sakamoto +9 more
202211 citations Open access
Semantic Scholar
Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial.
A. Ohba, H. Ueno, S. Shiba, N. Okano +12 more
2022European Journal of Cancer11 citations Open access
Semantic Scholar
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
Satoshi Kobayashi, Motoko Suzuki, M. Ueno, Y. Maruki +28 more
2022The Oncologist10 citations Open access
Semantic Scholar
Sex-related disparities in outcomes of cholangiocarcinoma patients in treatment trials
M. Ledenko, S. Antwi, S. Arima, Julia Driscoll +16 more
2022Frontiers in Oncology10 citations Open access
Semantic Scholar
A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer
C. Morizane, M. Ueno, M. Ikeda, Kentaro Sudo +5 more
2024BJC reports9 citations Open access
Semantic Scholar
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113
I. Yamada, C. Morizane, T. Okusaka, J. Mizusawa +34 more
2022Scientific Reports9 citations Open access
Semantic Scholar
Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial.
A. Ohba, C. Morizane, Y. Kawamoto, Y. Komatsu +16 more
2023Journal of Clinical Oncology8 citations Open access
Semantic Scholar
Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
J. Furuse, N. Izumi, K. Motomura, Y. Inaba +5 more
2023Drugs - Real World Outcomes8 citations Open access
Semantic Scholar
79P Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
A. Vogel, S. Chan, J. Furuse, W. Tak +10 more
2022Annals of Oncology8 citations Open access
Semantic Scholar
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).
C. Yoo, R. Finn, H. Klümpen, R. Kelley +16 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
937P Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
M. Ikeda, T. Yamashita, S. Ogasawara, M. Kudo +12 more
2021Annals of Oncology7 citations Open access
Semantic Scholar
A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT)
Shin Kobayashi, M. Ikeda, K. Nakachi, M. Ueno +6 more
2023Annals of Surgical Oncology6 citations
Semantic Scholar
FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
Satoshi Kobayashi, Shun Tezuka, Yui Yamachika, Shotaro Tsunoda +7 more
2023BMC Cancer6 citations Open access
Semantic Scholar
Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting
H. Imaoka, M. Ikeda, Satoshi Kobayashi, A. Ohba +33 more
2024Journal of gastroenterology5 citations Open access
Semantic Scholar
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
O. Crysler, M. Yarchoan, J. Furuse, P. Galle +9 more
2023Journal of Clinical Oncology5 citations
Semantic Scholar
Verification of a Merkle Patricia Tree Library Using F
Sota Sato, Ryotaro Banno, J. Furuse, Kohei Suenaga +1 more
2021arXiv.org5 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Ueno×20
Invite
M. Ueno — researcher profile on SciRah
M. Ikeda×20
Invite
M. Ikeda — researcher profile on SciRah
M. Kudo×15
Invite
M. Kudo — researcher profile on SciRah
T. Okusaka×14
Invite
T. Okusaka — researcher profile on SciRah

×13

Invite

C. Morizane — researcher profile on SciRah

Invite

M. Ozaka — researcher profile on SciRah

Invite

N. Okano — researcher profile on SciRah

Invite

A. Negro — researcher profile on SciRah

Invite

A. Todaka — researcher profile on SciRah

Satoshi Kobayashi×8

Invite

Satoshi Kobayashi — researcher profile on SciRah

G. Abou-Alfa×7

Invite

G. Abou-Alfa — researcher profile on SciRah

Invite

R. Kelley — researcher profile on SciRah